U.S. Food and Drug Administration (FDA)
Is NAD+ legal in United States?
Compounding restrictedNo FDA-approved NAD+ drug; FDA lists NAD in Category 1 (under evaluation), which lets 503A pharmacies compound it under FDA's interim policy
Pharmacy-made copies are tightly limited.
NAD+ (nicotinamide adenine dinucleotide) is on FDA's 503A Category 1 list, updated 14 May 2026, and beta-NAD is in Category 1 on FDA's 503B list (March 2025 version). Category 1 means FDA does not intend to act against compounders who meet the conditions in its interim policy while it evaluates the substance; it is not an approval and it is not the final 503A bulks list. FDA has warned telehealth firms not to claim that a compounded drug is FDA-approved, generic, or the same as an approved drug.
Last verified 2026-09-29 · how we verify
NAD+ elsewhere
Sources (4)
- 01Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories 1, 2 and 3)U.S. Food and Drug Administration · 2026-05-14 · accessed 2026-09-29
- 02Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (Categories 1, 2 and 3)U.S. Food and Drug Administration · 2025-03-21 · accessed 2026-09-29
- 03Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C ActU.S. Food and Drug Administration · 2026-05-14 · accessed 2026-09-29
- 04FDA to Telehealth Companies: What to Know When Promoting Compounded DrugsU.S. Food and Drug Administration · 2026-06-15 · accessed 2026-09-29